A novel delivery system has been developed for testosterone replacement. This formulation, COL-1621 (Striant), a testosterone-containing buccal mucoadhesive system, has been shown in preliminary studies to replace testosterone at physiological levels when used twice daily. Therefore, the current study compared the steady-state pharmacokinetics and tolerability of the buccal system with a testosterone-containing skin patch (Andropatch or Androderm) in an international multicenter study of a group of hypogonadal men.
and 12.15 nmol/liter (SD ‫؍‬ 5.55) in the transdermal patch group (P < 0.01). Of the patients treated with the buccal system, 97% had average steady-state testosterone concentrations within the physiological range (10.41-36.44 nmol/liter), whereas only 56% of the transdermal patch patients achieved physiological total testosterone concentrations (P < 0.001 between groups). Testosterone concentrations were within the physiological range in the buccal system group for a significantly greater portion of the 24-h treatment period than in the transdermal patch group (mean, 84.9% vs. 54.9%; P < 0.001). Testosterone/ dihydrotestosterone ratios were physiological and similar in both groups. Few patients experienced major adverse effects from either treatment. No significant local tolerability problems were noted with the buccal system, other than a single patient withdrawal. We conclude that this buccal system is superior to the transdermal patch in achieving testosterone concentrations within the normal range. It may, therefore, be a valuable addition to the range of choices for testosterone replacement therapy. T ESTOSTERONE REPLACEMENT THERAPY is indicated in hypogonadism, whether resulting from primary testicular failure (postinfectious testicular damage, bilateral orchidectomy, testicular injury, etc.), testicular failure secondary to gonadotropin deficiency (pituitary tumor, irradiation, etc.), or consequential to an inherited or acquired hypothalamic defect (hypothalamic hypogonadism caused by Kallmann's syndrome, hypothalamic tumors, idiopathic, etc.) (1) . The estimated prevalence of 5 per 1000 in the general community makes androgen deficiency the most common hormone deficiency disorder among men (2) . The oral bioavailability of testosterone is very low, and the only form of oral testosterone currently licensed for the treatment of hypogonadism has low efficacy and causes nonphysiological hormone profiles (3) . The other currently available testosterone formulations include testosterone implants (usually every 6 months), depot injections of testosterone enanthate or cypionate given at 1-to 4-wk intervals, the recently introduced injectable testosterone undecanoate given at 10-to 12-wk intervals, or daily skin patches or skin gel (4 -12) . However, some of these newer formulations are not generally available, and there still remains an unmet medical need for a testosterone formulation that is convenient to use and efficacious for most individuals.
Striant is a controlled-and sustained-release buccal mucoadhesive system containing 30 mg of testosterone and bioadhesive excipients. It was approved by the U.S. Food and Drug Administration June 19, 2003 , as "Striant (testosterone buccal system) mucoadhesive." In the current study, we compared the effect and the safety profile of this buccal system (administered twice daily) to a registered testosterone transdermal patch (5 mg, once a day) for the treatment of testosterone deficiency in men for 7 d in a randomized, open-label, multicenter, parallel arm study.
Patients and Methods
Patients and protocol disorders. Patient characteristics are shown in Table 1 . Testosteronedeficient men with a morning (0900 h) serum testosterone less than 6.94 nmol/liter, normal age-related prostate-specific antigen levels, and hematocrit less than 50 were included in the study. Patients with an American Urological Association System Index for Prostatism score greater than 7 were excluded. After an appropriate washout period of their previous testosterone replacement (Ͼ6 months for implants, Ͼ4 wk for injections, and Ͼ1 wk for skin patches), patients had a baseline series of blood investigations performed (including alanine aminotransferase, ␥-glutamyl transpeptidase, sodium, potassium, creatinine, total cholesterol, high-density lipoprotein, triglycerides, and glucose), a 12-lead electrocardiogram, blood count (including hemoglobin, hematocrit, white blood cell and differential count, and red blood cell count) and physical examination. If eligible for the study, they formally consented and then received either the buccal system (30 mg twice daily at 0800 and 2000 h) or the transdermal patch (5 mg once a day at 2200 h) in a randomized manner. Twice-daily blood samples were taken on d 3, 4, and 6, and multiple 24-h blood samples were taken on d 7 and 8. A follow-up visit with blood sampling occurred at 2-14 d after treatment was discontinued.
Twenty-nine of 33 patients in the buccal system group and 28 of 34 patients in the transdermal patch group completed the protocol without any protocol violations and were included in the efficacy analysis. Exclusion of these subjects did not influence the baseline population parameters. Four patients (12.1%) in the buccal system group and six patients (17.6%) in the transdermal patch group had a major protocol violation leading to exclusion of their data from the analysis. The most common violation was patients taking a disallowed medication (testosterone product) during the study (three patients in the buccal system group and five patients in the transdermal patch group). One patient in the buccal system group withdrew from the study after receiving 2 d of treatment and so did not provide any efficacy data for the primary endpoint, and one patient in the transdermal patch group violated the exclusion criterion regarding hematocrit (Ͼ50). No additional violations occurred that could potentially influence the interpretation of the efficacy data. Analysis on the basis of intention-to-treat analysis produced small changes in actual numbers but did not influence the overall significance of the data.
Serum was assayed for total testosterone [IMMULITE, Diagnostic Products Corp., Los Angeles, CA ( In each center, the appropriate ethical committee approval was sought and obtained before any patient was initiated into the trial, and all patients provided written informed consent.
Formulations
Andropatch (SmithKline Beecham Pharmaceuticals, Uxbridge, UK) or Androderm (Astra/Promed, Lutan, UK) 5 mg was supplied as single patches and used according to the manufacturers' instructions. In brief, a patch was applied once each day to a clean, dry, hairless area, and the site of application rotated over the course of 7 d. The buccal system (Striant) was supplied as a mucoadhesive system containing 30 mg of testosterone dispersed in a matrix containing the bioadhesive polymer, polycarbophil, along with other inert ingredients including hydroxypropylcellulose, monohydrated lactose, and cornstarch. The testosterone is slowly released from the matrix after buccal application. At application, each system was held in position on the gum above the right or left canine for a period of 30 sec. They were then left in situ for 12 h, after which the system was slid gently downward and replaced by another system for the next dosing interval.
Statistical analysis
Sample size estimation was performed on the basis of the following assumptions on the mean testosterone levels in steady state: average control mean total testosterone level was assumed to be 17.35 nmol/liter (sd ϭ 34%) and of the buccal system 19.09 nmol/liter (sd ϭ12%). Because mean serum concentrations less than 10.41 nmol/liter define testosterone deficiency, the effect size (d) of the control treatment vs. no treatment was estimated to be 6.94 nmol/liter. The noninferiority margin ␦ Ͻ d was set to 2/3(d) ϭ 4.65 nmol/liter. According to appropriate guidelines on statistics in clinical trails, the ␣-level for this one-sided comparison was set to 0.025. The power of the test (1 Ϫ ␤) was required to be 80%. Then sample size N per group was estimated using the following formula:
where z 1Ϫ␣ and z 1Ϫ␤ , denote the 100 ϫ (1 Ϫ ␣) % and the 100 ϫ (1 Ϫ 0.8) % points of the standard normal distribution, respectively. Because the sd of difference is not known a priori, calculations were made for different values of sd varying from 0.69 to 5.90 nmol/liter. As a conservative assumption, it is assumed that sd will not exceed 5.90 nmol/ liter; therefore, a sample size of 26 patients per group would be required. The noninferiority lower limit has been set to be above 80% for the ratio of least-squares geometric means, rather than above 4.65 nmol/liter for the difference between means. Ninety percent confidence intervals (CIs) for the originally planned difference between nontransformed means and the protocol-specified 95% CIs were also calculated.
The primary analysis, noninferiority, and the secondary analysis, superiority of the buccal system vs. the transdermal patch was calculated on the same endpoint by ANOVA using 95% CIs. Fisher's exact test, mean and sd, or median and minima and maxima were used as appropriate.
Pharmacokinetic analysis
Concentration vs. time data were summarized by noncompartmental estimation methods using the PK software program WinNonlin Professional (versions 3.1 and 3.2) (Pharsight, Mountain View, CA). The following pharmacokinetic parameters were analyzed:
• Maximum observed serum concentration (Cmax 0 -24 )
• Time-averaged steady-state serum concentration (Cavg 0 -24 )
• Minimum observed serum concentration (Cmin 0 -24 )
• Area under the serum concentration-time curve (AUC last ). The area under the curve (AUC) was calculated by the trapezoidal method. Missing data were calculated by interpolation. For the AUC calculations only, missing values were calculated by interpolation; otherwise, if blood samples were missing, concentrations were not reported. If a serum concentration was less than the lower limit of quantitation of the assay, it was deleted from the AUC calculation, except for the predose concentration at time 0 (t0) where a value of zero was assigned. Average concentration over a particular sampling interval for the buccal system and for the transdermal patch was calculated as: Cavg (t1 Ϫ t2) ϭ AUCt1 Ϫ t2/(t2 Ϫ t1), where t2 ϭ 12 h and t1 ϭ 0 h for the first 12-h sampling period, t2 ϭ 24 h and t1 ϭ 12 h for the second 12-h sampling period, and t2 ϭ 24 h and t1 ϭ 0 h for the 24-h sampling period.
• Percentage of time that serum concentrations were within the phys- An analysis was performed to assess the homogeneity of the treatment effects across centers by the inclusion of a treatment by center interaction term in the ANOVA model for the primary analysis. This term was not statistically significant and was therefore not included in the model. Hence, conclusions can be made consistently across all centers. The statistical package SAS (version 8.2; SAS Institute, Cary, NC) was used. Significance was taken at P Ͻ 0.05.
Results
Since the primary analysis, noninferiority, was met, these results focus on the secondary analysis, superiority. Use of the buccal system resulted in a steady maintained level of serum total testosterone in subjects that was generally in the normal range throughout (Fig. 1) . Mean testosterone levels on d 7 and 8 are shown in Fig. 2 . In the buccal system group, the mean concentrations at all time points were within the physiological range. By contrast, in the transdermal patch group, mean concentrations at five timepoints were outside of the physiological range. For both mean (0 -24 h) and minimum testosterone levels, the proportion of patients with values outside the physiological range was lower in the buccal system group than in the transdermal patch group, the differences being statistically significant (P Ͻ 0.001 for both). For peak testosterone levels, the proportion of patients with values outside the physiological range was higher in the buccal system group, although this was not statistically significant. The serum testosterone concentrations over the 24-h period were higher for patients receiving the buccal system than for patients in the transdermal patch group (mean AUC Ϯ sd, 451.31 Ϯ 140.71 h*nmol/liter vs. 304.63 Ϯ 134.46 h*nmol/liter; 95% CI 1.25, 1.91; P Ͻ 0.00001). For the buccal system group, the mean maximum 24-h testosterone (31.58 nmol/liter) and the mean minimum 24-h testosterone (11.10 nmol/liter) values were within the physiological range. For the transdermal patch group, the mean maximum 24-h testosterone levels (20.68 nmol/liter) were within the physiological range, but the mean minimum 24-h testosterone levels (5.76 nmol/liter) were below the physiological range. The proportion of subjects within the physiological range over 24 h was 84.8% for the buccal system and 55.1% for the patch group. The proportion of patients above 10.41 nmol/liter over 24 h was 88.4% for the buccal system group and 55.1% for the patch group. For the buccal system group, 27.7% had a peak level above 36.44 nmol/liter, whereas none were above this level in the patch group. Testosterone concentrations were within the physiological range in the buccal system group for a significantly greater portion of the 24-h treatment period than in the transdermal patch group (mean, 84.9% vs. 54.9%; P Ͻ 0.001). Overall, these results indicate that patients receiving the buccal system were more likely to have testosterone concentrations within the physiological range than patients receiving a transdermal patch.
Mean DHT levels were within the normal range (1.03-2.92 nmol/liter) for both the transdermal patch group (1.2 Ϯ 0.57 nmol/liter) and for the buccal system group (2.36 Ϯ 0.99 nmol/liter). The testosterone/DHT ratio was also similar in the transdermal patch (9.2) and buccal system groups (8.2). The concentration ratios for the buccal system group were relatively constant over the 24-h sampling period, and were within the expected normal physiological range (13) .
The median estradiol concentrations increased from baseline to d 7, and returned to baseline values at the follow-up visit. The median increase from baseline to d 7 was significantly greater in the buccal system group (55.07 pmol/liter) than in the transdermal patch group (34.87 pmol/liter; P Ͻ 0.001). After discontinuation of treatment, the levels rapidly returned to baseline values.
The percentage of patients reporting adverse events (AEs) in all body systems were similar between the two groups, with 17 patients (51.5%) in the buccal system group reporting a total of 28 AEs, and 16 patients (47.1%) in the transdermal patch group reporting a total of 37 AEs. A single patient was discontinued from the buccal system group due to tenderness and blistering of the gum. The most common AEs reported for both treatment groups were application-site disorders [reported by six patients (18.2%) in the buccal system group and six patients (17.6%) in the transdermal patch group]. Patients in both groups experienced application-site erythema [reported by two patients (6.1%) in the buccal system group and five patients (14.7%) in the transdermal patch group] and application-site irritation [two patients (6.1%) in the buccal system group and one patient (2.9%) in the transdermal patch group].
There were no clinically significant changes in mean or median hematology or clinical chemistry parameters from baseline to follow-up in either treatment group.
Discussion
Our study investigated the effect of a buccal testosterone preparation in hypogonadal men and compared its effects to a conventional testosterone skin patch. The data presented here demonstrate that the buccal system causes a steady mean testosterone level within the normal range and that the patients using the buccal system had testosterone levels in the normal range in a higher percentage of the day when compared with patients using the conventional patch. Patients taking the buccal system also had higher DHT levels than those on the patch, but the values were within the normal range. Slightly higher DHT levels were observed after a testosterone gel preparation (AndroGel) in a recent study (7) . Serum estradiol levels rose appropriately after both treatments in the present study. The buccal system appeared to be safe and well tolerated. The most common AE reported was an application-site reaction, but when this occurred it was generally mild and rarely caused interruption of treatment (other than in a single patient).
Current forms of injectable testosterone include the longestablished depot injections and implants. The depot injections currently consist of a mix of one or more oily esters, and are extremely cheap, but need to be repeated every 1-4 wk. They can also be painful by im injection. However, the most unacceptable aspect of these formulations is the grossly nonphysiological pharmacokinetic profiles of testosterone that they produce (6, 14) . This can be improved by giving smaller doses more frequently, e.g. 100 mg weekly, but clearly at the expense of comfort and convenience (14) . The recently introduced longer-acting injectable testosterone undecanoate needs injections every 10 -12 wk, and wider experience will establish its place in testosterone replacement therapy (10) . Implants are generally more acceptable to patients, but the actual implantation requires a surgical procedure, albeit a small one, and unless they are being performed in a center with considerable experience in their use, there can be unacceptably high extrusion rates. Oral testosterone undecanoate rarely produces physiological levels of testosterone and must be administered several times a day (15) .
The newer testosterone patches were thought originally to offer a superior form of replacement therapy, but due to the requirement for a high dose of testosterone to be delivered transdermally, the current patches are relatively large and can be cosmetically unsightly. The high rate of dermatological AEs experienced with some of these formulations has also limited their use (16) . The scrotal patch, although providing physiological levels of testosterone, results in supraphysiological levels of DHT as a consequence of the high rate of testosterone metabolism in scrotal skin compared with that at other dermal application sites (17) . There are increasing amounts of available data on the dermal gel formulation, suggesting it to be effective and without any application-site side effects and negligible interpersonal testosterone transfer (7-9, 11, 12, 18 -20) . A preliminary study of the use of a different, noncontrolled/sustained release buccal testosterone preparation has been reported earlier, where six subjects were taking one or two 10-mg buccal systems applied to the lower gum (21) . Testosterone levels rose to within the normal range and improved scores in sexual function were achieved, although the duration of the increased testosterone level after the application of the system was rather short (2-4 h) (21) . A sublingual preparation, cyclodextrin testosterone, has also been tested in the past, but limited experience is available with this preparation (22) . More recently, three doses of a buccal preparation were tested on healthy volunteers pretreated with gonadotropin agonist, and favorable hormone profiles were achieved (23) .
Our results show that this testosterone buccal system mucoadhesive produces physiological testosterone levels in hypogonadal men, and is superior to the transdermal patch in achieving testosterone concentrations within the normal range. It represents a promising new agent that requires further longer-term study.
